Further Evaluation of Rizatriptan in Menstrual Migraine: Retrospective Analysis of Long-term Data
Objective.—To determine the long‐term efficacy of oral rizatriptan 10‐mg wafers in the treatment of menstrual migraine attacks. Methods.—Data from an extension study where patients with migraine used rizatriptan 10 mg to treat moderate or severe migraine attacks occurring over periods of up to 6 mon...
Saved in:
| Published in | Headache Vol. 42; no. 9; pp. 917 - 923 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Boston, MA, USA
Blackwell Science Inc
01.10.2002
Blackwell |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Objective.—To determine the long‐term efficacy of oral rizatriptan 10‐mg wafers in the treatment of menstrual migraine attacks.
Methods.—Data from an extension study where patients with migraine used rizatriptan 10 mg to treat moderate or severe migraine attacks occurring over periods of up to 6 months were included in a retrospective analysis. Patients used a diary card to record details of each migraine attack and onset of menstruation. Attacks in women were classified as menstrual or nonmenstrual according to 3 time windows relative to onset of menstruation (day 0): −3 to +3 days (7‐day window), −2 to + 2 days (5‐day window), and 0 to +1 days (2‐day window). The analysis looked at the efficacy of rizatriptan 10 mg by menstrual category of attack for each definition on three measures: pain relief at 2 hours (reduction of pain to mild or none), pain free at 2 hours, 24‐hours sustained pain free (pain free at 2 hours with no headache recurrence and no use of additional medications from 2 to 24 hours).
Results.—Ninety‐five women used rizatriptan 10 mg to treat a total of 1,839 attacks. The percentage of menstrual attacks was 30% for the –3 to +3 days definition, 23% for the −2 to +2 days definition, and 11% for the 0 to +1 days definition. Rizatriptan 10 mg was equally effective in menstrual and nonmenstrual migraine attacks regardless of the definition used. For example, using the −3 to +3 days definition, 78% of menstrual migraine attacks were relieved at 2 hours after dosing compared with 78% of nonmenstrual attacks. Pain relief rates for the other definitions were as follows: −2 to +2 days, menstrual = 78%, nonmenstrual = 78%; 0 to +1 days, menstrual = 79%, and nonmenstrual = 78%. No differences between menstrual and nonmenstrual attacks were found for the 2‐hour pain free and 24‐hour sustained pain free measures for any of the three definitions.
Conclusion.—Rizatriptan 10‐mg wafers were equally effective in the treatment of menstrual and nonmenstrual migraine attacks occurring over 6 months, regardless of the precise definition of menstrual association used and even when the outcome criteria were very stringent. These data provide further evidence that triptans are effective treatments for menstrual migraine. |
|---|---|
| AbstractList | Objective.-To determine the long-term efficacy of oral rizatriptan 10-mg wafers in the treatment of menstrual migraine attacks. Methods.-Data from an extension study where patients with migraine used rizatriptan 10 mg to treat moderate or severe migraine attacks occurring over periods of up to 6 months were included in a retrospective analysis. Patients used a diary card to record details of each migraine attack and onset of menstruation. Attacks in women were classified as menstrual or nonmenstrual according to 3 time windows relative to onset of menstruation (day 0): -3 to +3 days (7-day window), -2 to + 2 days (5-day window), and 0 to +1 days (2-day window). The analysis looked at the efficacy of rizatriptan 10 mg by menstrual category of attack for each definition on three measures: pain relief at 2 hours (reduction of pain to mild or none), pain free at 2 hours, 24-hours sustained pain free (pain free at 2 hours with no headache recurrence and no use of additional medications from 2 to 24 hours). Results.-Ninety-five women used rizatriptan 10 mg to treat a total of 1,839 attacks. The percentage of menstrual attacks was 30% for the -3 to +3 days definition, 23% for the -2 to +2 days definition, and 11% for the 0 to +1 days definition. Rizatriptan 10 mg was equally effective in menstrual and nonmenstrual migraine attacks regardless of the definition used. For example, using the -3 to +3 days definition, 78% of menstrual migraine attacks were relieved at 2 hours after dosing compared with 78% of nonmenstrual attacks. Pain relief rates for the other definitions were as follows: -2 to +2 days, menstrual=78%, nonmenstrual=78%; 0 to +1 days, menstrual=79%, and nonmenstrual=78%. No differences between menstrual and nonmenstrual attacks were found for the 2-hour pain free and 24-hour sustained pain free measures for any of the three definitions. Conclusion.-Rizatriptan 10-mg wafers were equally effective in the treatment of menstrual and nonmenstrual migraine attacks occurring over 6 months, regardless of the precise definition of menstrual association used and even when the outcome criteria were very stringent. These data provide further evidence that triptans are effective treatments for menstrual migraine. Objective.—To determine the long‐term efficacy of oral rizatriptan 10‐mg wafers in the treatment of menstrual migraine attacks. Methods.—Data from an extension study where patients with migraine used rizatriptan 10 mg to treat moderate or severe migraine attacks occurring over periods of up to 6 months were included in a retrospective analysis. Patients used a diary card to record details of each migraine attack and onset of menstruation. Attacks in women were classified as menstrual or nonmenstrual according to 3 time windows relative to onset of menstruation (day 0): −3 to +3 days (7‐day window), −2 to + 2 days (5‐day window), and 0 to +1 days (2‐day window). The analysis looked at the efficacy of rizatriptan 10 mg by menstrual category of attack for each definition on three measures: pain relief at 2 hours (reduction of pain to mild or none), pain free at 2 hours, 24‐hours sustained pain free (pain free at 2 hours with no headache recurrence and no use of additional medications from 2 to 24 hours). Results.—Ninety‐five women used rizatriptan 10 mg to treat a total of 1,839 attacks. The percentage of menstrual attacks was 30% for the –3 to +3 days definition, 23% for the −2 to +2 days definition, and 11% for the 0 to +1 days definition. Rizatriptan 10 mg was equally effective in menstrual and nonmenstrual migraine attacks regardless of the definition used. For example, using the −3 to +3 days definition, 78% of menstrual migraine attacks were relieved at 2 hours after dosing compared with 78% of nonmenstrual attacks. Pain relief rates for the other definitions were as follows: −2 to +2 days, menstrual = 78%, nonmenstrual = 78%; 0 to +1 days, menstrual = 79%, and nonmenstrual = 78%. No differences between menstrual and nonmenstrual attacks were found for the 2‐hour pain free and 24‐hour sustained pain free measures for any of the three definitions. Conclusion.—Rizatriptan 10‐mg wafers were equally effective in the treatment of menstrual and nonmenstrual migraine attacks occurring over 6 months, regardless of the precise definition of menstrual association used and even when the outcome criteria were very stringent. These data provide further evidence that triptans are effective treatments for menstrual migraine. Objective .—To determine the long‐term efficacy of oral rizatriptan 10‐mg wafers in the treatment of menstrual migraine attacks. Methods .—Data from an extension study where patients with migraine used rizatriptan 10 mg to treat moderate or severe migraine attacks occurring over periods of up to 6 months were included in a retrospective analysis. Patients used a diary card to record details of each migraine attack and onset of menstruation. Attacks in women were classified as menstrual or nonmenstrual according to 3 time windows relative to onset of menstruation (day 0): −3 to +3 days (7‐day window), −2 to + 2 days (5‐day window), and 0 to +1 days (2‐day window). The analysis looked at the efficacy of rizatriptan 10 mg by menstrual category of attack for each definition on three measures: pain relief at 2 hours (reduction of pain to mild or none), pain free at 2 hours, 24‐hours sustained pain free (pain free at 2 hours with no headache recurrence and no use of additional medications from 2 to 24 hours). Results .—Ninety‐five women used rizatriptan 10 mg to treat a total of 1,839 attacks. The percentage of menstrual attacks was 30% for the –3 to +3 days definition, 23% for the −2 to +2 days definition, and 11% for the 0 to +1 days definition. Rizatriptan 10 mg was equally effective in menstrual and nonmenstrual migraine attacks regardless of the definition used. For example, using the −3 to +3 days definition, 78% of menstrual migraine attacks were relieved at 2 hours after dosing compared with 78% of nonmenstrual attacks. Pain relief rates for the other definitions were as follows: −2 to +2 days, menstrual = 78%, nonmenstrual = 78%; 0 to +1 days, menstrual = 79%, and nonmenstrual = 78%. No differences between menstrual and nonmenstrual attacks were found for the 2‐hour pain free and 24‐hour sustained pain free measures for any of the three definitions. Conclusion .—Rizatriptan 10‐mg wafers were equally effective in the treatment of menstrual and nonmenstrual migraine attacks occurring over 6 months, regardless of the precise definition of menstrual association used and even when the outcome criteria were very stringent. These data provide further evidence that triptans are effective treatments for menstrual migraine. To determine the long-term efficacy of oral rizatriptan 10-mg wafers in the treatment of menstrual migraine attacks.OBJECTIVETo determine the long-term efficacy of oral rizatriptan 10-mg wafers in the treatment of menstrual migraine attacks.Data from an extension study where patients with migraine used rizatriptan 10 mg to treat moderate or severe migraine attacks occurring over periods of up to 6 months were included in a retrospective analysis. Patients used a diary card to record details of each migraine attack and onset of menstruation. Attacks in women were classified as menstrual or nonmenstrual according to 3 time windows relative to onset of menstruation (day 0): -3 to +3 days (7-day window), -2 to + 2 days (5-day window), and 0 to +1 days (2-day window). The analysis looked at the efficacy of rizatriptan 10 mg by menstrual category of attack for each definition on three measures: pain relief at 2 hours (reduction of pain to mild or none), pain free at 2 hours, 24-hours sustained pain free (pain free at 2 hours with no headache recurrence and no use of additional medications from 2 to 24 hours).METHODSData from an extension study where patients with migraine used rizatriptan 10 mg to treat moderate or severe migraine attacks occurring over periods of up to 6 months were included in a retrospective analysis. Patients used a diary card to record details of each migraine attack and onset of menstruation. Attacks in women were classified as menstrual or nonmenstrual according to 3 time windows relative to onset of menstruation (day 0): -3 to +3 days (7-day window), -2 to + 2 days (5-day window), and 0 to +1 days (2-day window). The analysis looked at the efficacy of rizatriptan 10 mg by menstrual category of attack for each definition on three measures: pain relief at 2 hours (reduction of pain to mild or none), pain free at 2 hours, 24-hours sustained pain free (pain free at 2 hours with no headache recurrence and no use of additional medications from 2 to 24 hours).Ninety-five women used rizatriptan 10 mg to treat a total of 1,839 attacks. The percentage of menstrual attacks was 30% for the -3 to +3 days definition, 23% for the -2 to +2 days definition, and 11% for the 0 to +1 days definition. Rizatriptan 10 mg was equally effective in menstrual and nonmenstrual migraine attacks regardless of the definition used. For example, using the -3 to +3 days definition, 78% of menstrual migraine attacks were relieved at 2 hours after dosing compared with 78% of nonmenstrual attacks. Pain relief rates for the other definitions were as follows: -2 to +2 days, menstrual = 78%, nonmenstrual = 78%; 0 to +1 days, menstrual = 79%, and nonmenstrual = 78%. No differences between menstrual and nonmenstrual attacks were found for the 2-hour pain free and 24-hour sustained pain free measures for any of the three definitions.RESULTSNinety-five women used rizatriptan 10 mg to treat a total of 1,839 attacks. The percentage of menstrual attacks was 30% for the -3 to +3 days definition, 23% for the -2 to +2 days definition, and 11% for the 0 to +1 days definition. Rizatriptan 10 mg was equally effective in menstrual and nonmenstrual migraine attacks regardless of the definition used. For example, using the -3 to +3 days definition, 78% of menstrual migraine attacks were relieved at 2 hours after dosing compared with 78% of nonmenstrual attacks. Pain relief rates for the other definitions were as follows: -2 to +2 days, menstrual = 78%, nonmenstrual = 78%; 0 to +1 days, menstrual = 79%, and nonmenstrual = 78%. No differences between menstrual and nonmenstrual attacks were found for the 2-hour pain free and 24-hour sustained pain free measures for any of the three definitions.Rizatriptan 10-mg wafers were equally effective in the treatment of menstrual and nonmenstrual migraine attacks occurring over 6 months, regardless of the precise definition of menstrual association used and even when the outcome criteria were very stringent. These data provide further evidence that triptans are effective treatments for menstrual migraine.CONCLUSIONSRizatriptan 10-mg wafers were equally effective in the treatment of menstrual and nonmenstrual migraine attacks occurring over 6 months, regardless of the precise definition of menstrual association used and even when the outcome criteria were very stringent. These data provide further evidence that triptans are effective treatments for menstrual migraine. To determine the long-term efficacy of oral rizatriptan 10-mg wafers in the treatment of menstrual migraine attacks. Data from an extension study where patients with migraine used rizatriptan 10 mg to treat moderate or severe migraine attacks occurring over periods of up to 6 months were included in a retrospective analysis. Patients used a diary card to record details of each migraine attack and onset of menstruation. Attacks in women were classified as menstrual or nonmenstrual according to 3 time windows relative to onset of menstruation (day 0): -3 to +3 days (7-day window), -2 to + 2 days (5-day window), and 0 to +1 days (2-day window). The analysis looked at the efficacy of rizatriptan 10 mg by menstrual category of attack for each definition on three measures: pain relief at 2 hours (reduction of pain to mild or none), pain free at 2 hours, 24-hours sustained pain free (pain free at 2 hours with no headache recurrence and no use of additional medications from 2 to 24 hours). Ninety-five women used rizatriptan 10 mg to treat a total of 1,839 attacks. The percentage of menstrual attacks was 30% for the -3 to +3 days definition, 23% for the -2 to +2 days definition, and 11% for the 0 to +1 days definition. Rizatriptan 10 mg was equally effective in menstrual and nonmenstrual migraine attacks regardless of the definition used. For example, using the -3 to +3 days definition, 78% of menstrual migraine attacks were relieved at 2 hours after dosing compared with 78% of nonmenstrual attacks. Pain relief rates for the other definitions were as follows: -2 to +2 days, menstrual = 78%, nonmenstrual = 78%; 0 to +1 days, menstrual = 79%, and nonmenstrual = 78%. No differences between menstrual and nonmenstrual attacks were found for the 2-hour pain free and 24-hour sustained pain free measures for any of the three definitions. Rizatriptan 10-mg wafers were equally effective in the treatment of menstrual and nonmenstrual migraine attacks occurring over 6 months, regardless of the precise definition of menstrual association used and even when the outcome criteria were very stringent. These data provide further evidence that triptans are effective treatments for menstrual migraine. |
| Author | Silberstein, Stephen D. Massiou, Helene Lines, Christopher R. McCarroll, Kathleen A. |
| Author_xml | – sequence: 1 givenname: Stephen D. surname: Silberstein fullname: Silberstein, Stephen D. organization: From the Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania – sequence: 2 givenname: Helene surname: Massiou fullname: Massiou, Helene organization: Department of Neurology, Hôpital Lariboisière, Paris, France – sequence: 3 givenname: Kathleen A. surname: McCarroll fullname: McCarroll, Kathleen A. organization: Merck & Co., Inc., West Point, Pennsylvania – sequence: 4 givenname: Christopher R. surname: Lines fullname: Lines, Christopher R. organization: Merck & Co., Inc., West Point, Pennsylvania |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14020617$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/12390621$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVkdFu0zAUhi00xLrBK6DcgHaTcuw4dsIFUrV1LVIHqAKBdmOdus5wSZ1iO6Pl6UnWsklcILiyZX__f6TznZAj1zhDSEJhSIGLV6shzZlIuegeGAAbAmOUD7ePyOD-44gMAKhMC8mLY3ISwgqgy5biCTmmLCtBMDogeNn6-NX4ZHyLdYvRNi5pqmRuf2L0dhPRJdYlV8aF6Fuskyt749E68zqZm-ibsDE62luTjBzWu2BDH5417iaNxq-TC4z4lDyusA7m2eE8JZ8uxx_Pp-ns_eTt-WiWai4kT4WsWMXyapkVmEuAYlEyjhqwBGlKXDBeFlW2KPky61ZQMk2XJRNCF3qxlFCY7JS83PdufPO9NSGqtQ3a1DU607RBSZZTXoDswLO_gjQXQLNcZNChzw9ou1ibpdp4u0a_U7_31wEvDgAGjXXl0WkbHjgODATtZxZ7Tnc7C95UDwioXqlaqd6c6s2pXqm6U6q2XfTNH1Ft452o2Jmo_6Pgh63N7p8Hq-l4dNFfu4J0X2BDNNv7AvTflJCZzNXndxM1-XA9nU2v5-pL9gt_wshj |
| CODEN | HEADAE |
| CitedBy_id | crossref_primary_10_2165_00023210_200519110_00005 crossref_primary_10_1517_14656566_2011_594794 crossref_primary_10_1080_14656566_2017_1414182 crossref_primary_10_1111_j_1526_4610_2008_01335_x crossref_primary_10_1517_14656566_2014_947959 crossref_primary_10_1111_j_1468_1331_2005_01076_x crossref_primary_10_1177_1756285612470191 crossref_primary_10_1517_14656566_8_11_1605 crossref_primary_10_1177_0333102415575723 crossref_primary_10_1111_j_1468_2982_2004_00741_x crossref_primary_10_1007_s00415_022_11477_1 crossref_primary_10_1111_j_1468_2982_2007_01313_x crossref_primary_10_1097_NRL_0b013e31805c746f crossref_primary_10_1007_s10194_012_0455_4 crossref_primary_10_1586_14737175_7_9_1105 crossref_primary_10_62087_hpr_2024_0004 crossref_primary_10_1007_s11916_011_0212_4 crossref_primary_10_1080_14656566_2023_2194487 crossref_primary_10_1111_j_1526_4610_2008_01093_x crossref_primary_10_1007_s11916_012_0280_0 crossref_primary_10_1111_j_1526_4610_2008_01304_x crossref_primary_10_2147_nedt_2006_2_3_247 crossref_primary_10_1016_S1474_4422_20_30482_8 crossref_primary_10_1783_147118907779399684 crossref_primary_10_1007_s11916_009_0016_y crossref_primary_10_1111_j_1526_4610_2007_00947_x crossref_primary_10_1111_j_1526_4610_2010_01625_x crossref_primary_10_1586_14737175_8_5_723 crossref_primary_10_1007_s11916_004_0057_1 crossref_primary_10_1007_s11916_012_0282_y crossref_primary_10_1517_14656566_9_6_1001 crossref_primary_10_1007_s10194_011_0366_9 crossref_primary_10_1007_s11916_022_01052_8 crossref_primary_10_1177_03331024241252666 crossref_primary_10_4137_CMT_S6170 crossref_primary_10_1007_s13760_017_0802_y crossref_primary_10_1007_s10072_011_0547_y crossref_primary_10_1007_s11940_004_0006_7 crossref_primary_10_1177_03331024221118929 crossref_primary_10_2165_11538090_000000000_00000 |
| Cites_doi | 10.1177/0333102497017S2011 10.1046/j.1468-2982.1999.019005525.x 10.1016/S0140-6736(97)11370-8 10.1212/WNL.45.6.1076 10.1046/j.1468-2982.2000.00117.x 10.1046/j.1468-2982.1990.1006305.x 10.1001/jama.1992.03480010072027 10.1212/WNL.55.10.1517 10.1016/S0029-7844(00)00880-2 10.1111/j.1526-4610.1993.hed3307385.x 10.1007/s11940-001-0054-1 10.1111/j.1468-2982.1999.1901016.x |
| ContentType | Journal Article |
| Copyright | 2003 INIST-CNRS |
| Copyright_xml | – notice: 2003 INIST-CNRS |
| DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TK 7X8 |
| DOI | 10.1046/j.1526-4610.2002.02214.x |
| DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | Neurosciences Abstracts CrossRef MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1526-4610 |
| EndPage | 923 |
| ExternalDocumentID | 12390621 14020617 10_1046_j_1526_4610_2002_02214_x HEAD2214 ark_67375_WNG_GPZHLHZR_X |
| Genre | shortCommunication Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29I 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5RE 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AAQQT AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABIVO ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AI. AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS ECV EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FYBCS G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 VH1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQ9 WQJ WRC WVDHM WXI WXSBR XG1 YCJ YFH YUY ZGI ZXP ZZTAW ~IA ~WT AAHQN AAIPD AAMNL AANHP AAYCA ACRPL ACYXJ ADNMO AFWVQ ALVPJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM PKN 7TK 7X8 |
| ID | FETCH-LOGICAL-c4674-67f2f25fd38a57008b924ac0a907e9ab2498f3b94d310492c1d9266c8cbd708e3 |
| IEDL.DBID | DR2 |
| ISSN | 0017-8748 |
| IngestDate | Fri Jul 11 00:45:16 EDT 2025 Fri Jul 11 10:10:31 EDT 2025 Wed Feb 19 02:34:42 EST 2025 Mon Jul 21 09:15:10 EDT 2025 Thu Apr 24 23:09:59 EDT 2025 Tue Jul 01 00:33:34 EDT 2025 Wed Jan 22 17:08:27 EST 2025 Wed Oct 30 09:51:02 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | Human Nervous system diseases Agonist Menstruation Prognosis Antimigrainous agent Migraine Oral administration Tryptamine derivatives Cardiovascular disease Serotonine receptor Serotonin agonist Long term Cerebral disorder Vascular disease Chemotherapy Pain Treatment Central nervous system disease Adult Female Rizatriptan Indole derivatives Cerebrovascular disease |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4674-67f2f25fd38a57008b924ac0a907e9ab2498f3b94d310492c1d9266c8cbd708e3 |
| Notes | istex:327C3BB3FBE2BCBEC31B22B3F2758C0393EA2E18 ark:/67375/WNG-GPZHLHZR-X ArticleID:hed2214 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
| PMID | 12390621 |
| PQID | 1560135630 |
| PQPubID | 23462 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_72514807 proquest_miscellaneous_1560135630 pubmed_primary_12390621 pascalfrancis_primary_14020617 crossref_primary_10_1046_j_1526_4610_2002_02214_x crossref_citationtrail_10_1046_j_1526_4610_2002_02214_x wiley_primary_10_1046_j_1526_4610_2002_02214_x_HEAD2214 istex_primary_ark_67375_WNG_GPZHLHZR_X |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | October 2002 |
| PublicationDateYYYYMMDD | 2002-10-01 |
| PublicationDate_xml | – month: 10 year: 2002 text: October 2002 |
| PublicationDecade | 2000 |
| PublicationPlace | Boston, MA, USA |
| PublicationPlace_xml | – name: Boston, MA, USA – name: Malden, MA – name: United States |
| PublicationTitle | Headache |
| PublicationTitleAlternate | Headache: The Journal of Head and Face Pain |
| PublicationYear | 2002 |
| Publisher | Blackwell Science Inc Blackwell |
| Publisher_xml | – name: Blackwell Science Inc – name: Blackwell |
| References | Ahrens SP, Farmer MV, Williams DL, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia. 1999;19: 525-530. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000;20: 765-786. Johannes CB, Linet MS, Stewart WF, Celentano DD, Lipton RB, Szklo M. Relationship of headache to phase of the menstrual cycle among young women: a daily diary study. Neurology. 1995;45: 1076-1082. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and non-menstrual attacks in women with menstrually related migraine [abstract]. Cephalalgia. 2001;21: 263-264. Silberstein SD, Massiou H, Le Jeunne C, Johnson-Pratt L, McCarroll KA, Lines CR. Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol. 2000;96: 237-242. Granella F, Sances G, Nanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache. 1993;33: 385-389. Silberstein SD. The role of sex hormones in headache. Neurology. 1992;42(Suppl 2):37-42. Massiou H, Silberstein SD, McCarroll KA, Allen C, Lines CR. Efficacy of rizatriptan in menstrual migraine: freedom from pain and associated symptoms at 2-h and 24-h sustained pain free status [abstract]. Cephalalgia. 2000;20: 343-344. Loder E, Silberstein SD. Efficacy of zolmitriptan in the acute treatment of menstrually associated migraine [abstract]. Headache. 1999;39: 366. Stewart WF, Lipton RB, Chee E, et al. Menstrual cycle and headache in a population sample of migraineurs. Neurology. 2000;55: 1517-1523. Ferrari MD. Migraine. Lancet. 1998;351: 1043-1051. Loder E. Menstrual migraine. Curr Treatm Opt Neurol. 2001;3: 189-200. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine in the United States: relation to age, income, race and other sociodemographic factors. JAMA. 1992;287: 64-69. MacGregor EA, Chia H, Vohrah RC, Wilkinson M. Migraine and menstruation: a pilot study. Cephalalgia. 1990;10: 305-310. MacGregor A. Migraine associated with menstruation. Funct Neurol. 2000;15(suppl 1):143-153 Granella F, Sances G, Messa G, De Marenis M, Manzoni GC. Treatment of menstrual migraine. Cephalalgia. 1997;17(suppl 20):35-38. Salonen R, Saiers J. Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses. Cephalalgia. 1999;19: 16-19. Gross MLP, Barrie M, Bates D, Dowson A, Elrington G. The efficacy of oral sumatriptan in menstrual migraine-a prospective study [abstract]. Cephalalgia. 1995;15(suppl 4):227. 1990; 10 2000; 15 1999; 19 1995; 15 1992; 287 1993; 33 1999; 39 1995; 45 2000; 55 2000; 96 1988; 8 2000; 20 1997; 17 2001; 3 1993 1992; 42 1998; 351 2001; 21 Gross MLP (e_1_2_6_22_2) 1995; 15 Silberstein SD (e_1_2_6_5_2) 1992; 42 Granella F (e_1_2_6_9_2) 2001; 21 Bousser M‐G (e_1_2_6_7_2) 1993 MacGregor A (e_1_2_6_20_2) 2000; 15 e_1_2_6_8_2 Loder E (e_1_2_6_12_2) 1999; 39 e_1_2_6_18_2 e_1_2_6_19_2 e_1_2_6_4_2 e_1_2_6_3_2 e_1_2_6_6_2 e_1_2_6_13_2 Massiou H (e_1_2_6_14_2) 2000; 20 e_1_2_6_2_2 e_1_2_6_10_2 e_1_2_6_11_2 e_1_2_6_21_2 e_1_2_6_16_2 Headache Classification Committee of the International Headache Society (e_1_2_6_17_2) 1988; 8 e_1_2_6_15_2 |
| References_xml | – reference: MacGregor EA, Chia H, Vohrah RC, Wilkinson M. Migraine and menstruation: a pilot study. Cephalalgia. 1990;10: 305-310. – reference: Salonen R, Saiers J. Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses. Cephalalgia. 1999;19: 16-19. – reference: Loder E, Silberstein SD. Efficacy of zolmitriptan in the acute treatment of menstrually associated migraine [abstract]. Headache. 1999;39: 366. – reference: Johannes CB, Linet MS, Stewart WF, Celentano DD, Lipton RB, Szklo M. Relationship of headache to phase of the menstrual cycle among young women: a daily diary study. Neurology. 1995;45: 1076-1082. – reference: Massiou H, Silberstein SD, McCarroll KA, Allen C, Lines CR. Efficacy of rizatriptan in menstrual migraine: freedom from pain and associated symptoms at 2-h and 24-h sustained pain free status [abstract]. Cephalalgia. 2000;20: 343-344. – reference: Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96. – reference: Loder E. Menstrual migraine. Curr Treatm Opt Neurol. 2001;3: 189-200. – reference: Granella F, Sances G, Allais G, et al. Characteristics of menstrual and non-menstrual attacks in women with menstrually related migraine [abstract]. Cephalalgia. 2001;21: 263-264. – reference: MacGregor A. Migraine associated with menstruation. Funct Neurol. 2000;15(suppl 1):143-153 – reference: Stewart WF, Lipton RB, Chee E, et al. Menstrual cycle and headache in a population sample of migraineurs. Neurology. 2000;55: 1517-1523. – reference: Ferrari MD. Migraine. Lancet. 1998;351: 1043-1051. – reference: Ahrens SP, Farmer MV, Williams DL, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia. 1999;19: 525-530. – reference: Granella F, Sances G, Messa G, De Marenis M, Manzoni GC. Treatment of menstrual migraine. Cephalalgia. 1997;17(suppl 20):35-38. – reference: Silberstein SD, Massiou H, Le Jeunne C, Johnson-Pratt L, McCarroll KA, Lines CR. Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol. 2000;96: 237-242. – reference: Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine in the United States: relation to age, income, race and other sociodemographic factors. JAMA. 1992;287: 64-69. – reference: Gross MLP, Barrie M, Bates D, Dowson A, Elrington G. The efficacy of oral sumatriptan in menstrual migraine-a prospective study [abstract]. Cephalalgia. 1995;15(suppl 4):227. – reference: Granella F, Sances G, Nanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache. 1993;33: 385-389. – reference: International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000;20: 765-786. – reference: Silberstein SD. The role of sex hormones in headache. Neurology. 1992;42(Suppl 2):37-42. – volume: 8 start-page: 1 issue: suppl 7 year: 1988 end-page: 96 article-title: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. publication-title: Cephalalgia – volume: 17 start-page: 35 issue: suppl 20 year: 1997 end-page: 38 article-title: Treatment of menstrual migraine. publication-title: Cephalalgia – volume: 19 start-page: 16 year: 1999 end-page: 19 article-title: Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses. publication-title: Cephalalgia – volume: 3 start-page: 189 year: 2001 end-page: 200 article-title: Menstrual migraine. publication-title: Curr Treatm Opt Neurol – volume: 351 start-page: 1043 year: 1998 end-page: 1051 article-title: Migraine. publication-title: Lancet – volume: 10 start-page: 305 year: 1990 end-page: 310 article-title: Migraine and menstruation: a pilot study. publication-title: Cephalalgia – volume: 15 start-page: 143 issue: suppl 1 year: 2000 end-page: 153 article-title: Migraine associated with menstruation. publication-title: Funct Neurol – volume: 19 start-page: 525 year: 1999 end-page: 530 article-title: Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. publication-title: Cephalalgia – volume: 42 start-page: 37 issue: Suppl 2 year: 1992 end-page: 42 article-title: The role of sex hormones in headache. publication-title: Neurology – volume: 21 start-page: 263 year: 2001 end-page: 264 article-title: Characteristics of menstrual and non‐menstrual attacks in women with menstrually related migraine [abstract]. publication-title: Cephalalgia – volume: 15 start-page: 227 issue: suppl 4 year: 1995 article-title: The efficacy of oral sumatriptan in menstrual migraine—a prospective study [abstract]. publication-title: Cephalalgia – volume: 55 start-page: 1517 year: 2000 end-page: 1523 article-title: Menstrual cycle and headache in a population sample of migraineurs. publication-title: Neurology – volume: 287 start-page: 64 year: 1992 end-page: 69 article-title: Prevalence of migraine in the United States: relation to age, income, race and other sociodemographic factors. publication-title: JAMA – start-page: 413 year: 1993 end-page: 420 – volume: 20 start-page: 343 year: 2000 end-page: 344 article-title: Efficacy of rizatriptan in menstrual migraine: freedom from pain and associated symptoms at 2‐h and 24‐h sustained pain free status [abstract]. publication-title: Cephalalgia – volume: 20 start-page: 765 year: 2000 end-page: 786 article-title: Guidelines for controlled trials of drugs in migraine: second edition. publication-title: Cephalalgia – volume: 45 start-page: 1076 year: 1995 end-page: 1082 article-title: Relationship of headache to phase of the menstrual cycle among young women: a daily diary study. publication-title: Neurology – volume: 39 start-page: 366 year: 1999 article-title: Efficacy of zolmitriptan in the acute treatment of menstrually associated migraine [abstract]. publication-title: Headache – volume: 96 start-page: 237 year: 2000 end-page: 242 article-title: Rizatriptan in the treatment of menstrual migraine. publication-title: Obstet Gynecol – volume: 33 start-page: 385 year: 1993 end-page: 389 article-title: Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. publication-title: Headache – volume: 39 start-page: 366 year: 1999 ident: e_1_2_6_12_2 article-title: Efficacy of zolmitriptan in the acute treatment of menstrually associated migraine [abstract]. publication-title: Headache – ident: e_1_2_6_16_2 – start-page: 413 volume-title: The headaches year: 1993 ident: e_1_2_6_7_2 – ident: e_1_2_6_8_2 doi: 10.1177/0333102497017S2011 – volume: 20 start-page: 343 year: 2000 ident: e_1_2_6_14_2 article-title: Efficacy of rizatriptan in menstrual migraine: freedom from pain and associated symptoms at 2‐h and 24‐h sustained pain free status [abstract]. publication-title: Cephalalgia – volume: 15 start-page: 143 issue: 1 year: 2000 ident: e_1_2_6_20_2 article-title: Migraine associated with menstruation. publication-title: Funct Neurol – volume: 42 start-page: 37 issue: 2 year: 1992 ident: e_1_2_6_5_2 article-title: The role of sex hormones in headache. publication-title: Neurology – ident: e_1_2_6_15_2 doi: 10.1046/j.1468-2982.1999.019005525.x – ident: e_1_2_6_19_2 doi: 10.1016/S0140-6736(97)11370-8 – ident: e_1_2_6_3_2 doi: 10.1212/WNL.45.6.1076 – ident: e_1_2_6_18_2 doi: 10.1046/j.1468-2982.2000.00117.x – ident: e_1_2_6_6_2 doi: 10.1046/j.1468-2982.1990.1006305.x – ident: e_1_2_6_2_2 doi: 10.1001/jama.1992.03480010072027 – ident: e_1_2_6_10_2 doi: 10.1212/WNL.55.10.1517 – volume: 8 start-page: 1 issue: 7 year: 1988 ident: e_1_2_6_17_2 article-title: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. publication-title: Cephalalgia – ident: e_1_2_6_13_2 doi: 10.1016/S0029-7844(00)00880-2 – ident: e_1_2_6_4_2 doi: 10.1111/j.1526-4610.1993.hed3307385.x – ident: e_1_2_6_21_2 doi: 10.1007/s11940-001-0054-1 – volume: 21 start-page: 263 year: 2001 ident: e_1_2_6_9_2 article-title: Characteristics of menstrual and non‐menstrual attacks in women with menstrually related migraine [abstract]. publication-title: Cephalalgia – volume: 15 start-page: 227 issue: 4 year: 1995 ident: e_1_2_6_22_2 article-title: The efficacy of oral sumatriptan in menstrual migraine—a prospective study [abstract]. publication-title: Cephalalgia – ident: e_1_2_6_11_2 doi: 10.1111/j.1468-2982.1999.1901016.x |
| SSID | ssj0004696 |
| Score | 1.8609861 |
| Snippet | Objective.—To determine the long‐term efficacy of oral rizatriptan 10‐mg wafers in the treatment of menstrual migraine attacks.
Methods.—Data from an extension... Objective .—To determine the long‐term efficacy of oral rizatriptan 10‐mg wafers in the treatment of menstrual migraine attacks. Methods .—Data from an... To determine the long-term efficacy of oral rizatriptan 10-mg wafers in the treatment of menstrual migraine attacks. Data from an extension study where... Objective.-To determine the long-term efficacy of oral rizatriptan 10-mg wafers in the treatment of menstrual migraine attacks. Methods.-Data from an extension... To determine the long-term efficacy of oral rizatriptan 10-mg wafers in the treatment of menstrual migraine attacks.OBJECTIVETo determine the long-term... |
| SourceID | proquest pubmed pascalfrancis crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 917 |
| SubjectTerms | Administration, Oral Adult Biological and medical sciences Cardiovascular system Female Humans Medical sciences menstruation Menstruation - physiology migraine Migraine Disorders - drug therapy Migraine Disorders - physiopathology Pharmacology. Drug treatments Retrospective Studies rizatriptan Serotonin Receptor Agonists - administration & dosage Serotonin Receptor Agonists - therapeutic use Triazoles - administration & dosage Triazoles - therapeutic use Tryptamines Vasodilator agents. Cerebral vasodilators |
| Title | Further Evaluation of Rizatriptan in Menstrual Migraine: Retrospective Analysis of Long-term Data |
| URI | https://api.istex.fr/ark:/67375/WNG-GPZHLHZR-X/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1046%2Fj.1526-4610.2002.02214.x https://www.ncbi.nlm.nih.gov/pubmed/12390621 https://www.proquest.com/docview/1560135630 https://www.proquest.com/docview/72514807 |
| Volume | 42 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEB1KCqWXpulXnDapCqU3L2v5S-4tNLsxIRvK0tAlFyHJUki32GGzCyGn_oT-xvySaCR70y0phNCbDx4Zj2ekJ2vmPYCPGWOpiPEL2Bk4TJS2OUeNCI2iNFcsMoVrHxsdZeVxcjBJJ239E_bCeH6I5Q83zAw3X2OCC-lVSPqO3fYHSvdkIfKFu0qDnl2NoqSHeBJLtxAfjekfLZJOqstPynnC2qKe9oDzzoFWVqrH6PRLrJwUF9Z5xqte3AVLV1GuW6aG6zDtXtBXp0x7i7nsqau_uB__jweew7MWzZJdH34b8EjXL-DJqD2vfwlquJghwiSDJak4aQwZY_MnzlaiJmc1GWlHY2sHGp2domSF_kzGej5rujZQ0lGnoPFhU59e__qNSwrZE3PxCo6Hg29fyrCVdQgVSpuEWW6ooampYiaQXZ9JuwcUqi_sPl0XQtoNITOxLJLKQs-koCqqCgsjFFOyyvtMx69hrW5qvQlEJxVSTGpVZUisqAspC5VWsaIiVUWcBZB3n5CrlvMcpTd-cnf2nmCfGvqQow9RkZNy50N-GUC0tDz3vB_3sPnkomRpIGZTrJvLU_79aJ_vfz0pD8uTMZ8EsLMSRrdPwN28xZQBfOjiitt0xzMcUetmccGx8T2KkdQtgPf_uCe3mBWZAgJ440PydnwaIy91ZP3iAuver8bLwe4eXm492PItPPVKOlgI-Q7WbFzpbQvo5nLHpeoN3dc6kw |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VVoJeeEPDozUScMvSOG8kDhW725TurtCqFatejOM4VVWUoH2IhRM_gf_DX-HEL2HGSbYsKlKF1AO3HDJO7HnanvkG4GkQRb50iQNogW1PadQ5nks7V5yHKnLy2JSP9QdBcui9GfmjFfje1MJU-BCLAzfSDGOvScHpQPpFfS1ZabnPA5sAw02qQQvdkeO15nWG5b7-_An3b5NXe21k9jPOu52D14ldtxiwFbXZsIMw5zn388yNJCG9RynuR6Talrhn1LFMcXMS5W4aexmGQV7MlZPF6NJUpNIs3I60i-NegTVqKE7A_e0h_60o0zQHq9xA6EV1GlF9pXruny_5xjVi85xyNeUE2ZVXfTbOC4SX42rjGLs34EezpFU-zGlrNk1b6ssfaJP_6ZrfhOt1wM52Kg27BSu6uA1X-3VKwh1Q3dmYgmjWWeCmszJnQ6pvJYMsC3ZSsL42SL04UP_kmLpy6JdsqKfjsql0ZQ06DBH3yuL459dv5DVZW07lXTi8lCneg9WiLPQGMO1lhKKpVRYQdqSO0zRWfuYqLn0Vu4EFYSMzQtWw7tRd5IMw6QUeleIRzwTxjJqOcmF4JuYWOAvKjxW0yQVonhuxXBDI8SmlBoa-eDfYFbtvj5JecjQUIws2l-T27At0YIFhswVPGkEWaNHomkoWupxNBNX2Oy7h1lmw9Zd3QgzLCQzBgvuVDpyNz12C3nZwXYwkX3hqIunstOnxwT9TbsG15KDfE729wf5DWK8aB1He5yNYRRnTjzF-naabxk4weH_ZSvILpPaW4A |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtNAFL0qrVSx4f1wgXaQgJ3TePxGYlHhpC5NoiqiIupmGI9nqqqVXeUhAis-ge_hV9jxJcwd2ylBRaqQumCXRe4knvscz7nnArwIosjnLmpAR2DbE1L7HFXcVoLSUESOik37WH8QpIfeu5E_WoHvTS9MxQ-xeOGGnmHiNTr4ea6261vJysl9GtjIF26QBi2djRyvNa8Blvvy8yd9fJu82Uu0rl9S2u28f5va9YQBW-CUDTsIFVXUV7kbcSR6jzJ9HOGizfWRUcY802eTSLlZ7OW6CvJiKpw81hlNRCLLw3YkXb3uDVjzgnaMYyOSIf2tJ9PMBquyQOhFNYqovlG99J8vpcY11PIcoZp8orWlqjEbl9XBy2W1yYvd2_Cj2dEKDnPamk2zlvjyB9nk_7nld-BWXa6Tncq_7sKKLO7Ber8GJNwH0Z2NsYQmnQVrOikVGWJ3K4ZjXpCTgvSl4enVC_VPjnEmh3xNhnI6Lps-V9Jww6BwryyOf379hjmTJHzKH8DhtTziQ1gtykI-BiK9HDk0pcgDZI6UcZbFws9dQbkvYjewIGxMhoma1B1ni5wxAy7wsBEPdcZQZzhylDKjMza3wFlInlfEJleQeWWsciHAx6cIDAx99mGwy3YPjtJeejRkIws2l8z24hfwdYUumi143tgx0_EML6l4IcvZhGFnv-Mia50FW3_5TqiLcqRCsOBR5QIX61MXibcdvS_GkK_8aCzt7CT4ceOfJbdg_SDpst7eYP8J3KymBiHo8ymsahOTz3TxOs02TZQg8PG6feQXH9qVjw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Further+Evaluation+of+Rizatriptan+in+Menstrual+Migraine%3A+Retrospective+Analysis+of+Long-term+Data&rft.jtitle=Headache&rft.au=Silberstein%2C+Stephen+D.&rft.au=Massiou%2C+Helene&rft.au=McCarroll%2C+Kathleen+A.&rft.au=Lines%2C+Christopher+R.&rft.date=2002-10-01&rft.pub=Blackwell+Science+Inc&rft.issn=0017-8748&rft.eissn=1526-4610&rft.volume=42&rft.issue=9&rft.spage=917&rft.epage=923&rft_id=info:doi/10.1046%2Fj.1526-4610.2002.02214.x&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_GPZHLHZR_X |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0017-8748&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0017-8748&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0017-8748&client=summon |